NDASUBCUTANEOUSSOLUTION
Approved
Apr 2008
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
9
Data completeness
5/8 — Partial
RELISTOR (methylnaltrexone bromide) by Bausch Health is mu-opioid receptor. Approved for opioid-induced constipation (oic) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer, its treatment and 4 more indications. First approved in 2008.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RELISTOR (methylnaltrexone bromide) is a peripherally-acting mu-opioid receptor antagonist administered via subcutaneous injection for opioid-induced constipation (OIC). It selectively blocks opioid effects in the gastrointestinal tract without crossing the blood-brain barrier, preserving central analgesic benefits. Indicated for OIC in chronic non-cancer pain, advanced illness, and cancer pain populations.
Peak4.5 years to LOE
Product is at peak commercial maturity with stable market presence; teams are focused on defending market share against emerging competitors rather than driving rapid growth.
Mechanism of Action
mu-opioid receptor. As a quaternary amine, the ability of methylnaltrexone to cross the blood-brain barrier is restricted. This allows methylnaltrexone to function as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the…
Worked on RELISTOR at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.